Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.36 |
| ▸ | LMNA | P02545 | 6/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 2/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | AKT2 | P31751 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13487373 | 0.95 | TDP1 (0.36) | TDP1KDM4ELMNAALDH1A1GAA | |
| SCHEMBL13487292 | 0.94 | KDM4E (0.36) | TDP1KDM4ELMNAALDH1A1GAA | |
| SCHEMBL13487182 | 0.93 | TDP1 (0.36) | TDP1KDM4ELMNAALDH1A1GAA | |
| SCHEMBL13487118 | 0.92 | KDM4E (0.38) | TDP1KDM4ELMNAALDH1A1GAA | |
| SCHEMBL13487072 | 0.90 | ALDH1A1 (0.44) | TDP1KDM4ELMNAALDH1A1GAA | |
| SCHEMBL13487122 | 0.89 | ESR1 (0.36) | LMNAALDH1A1NPSR1DHODHSMN1; SMN2 | |
| SCHEMBL13487375 | 0.88 | ALDH1A1 (0.36) | TDP1KDM4ELMNAALDH1A1GAA | |
| SCHEMBL13487908 | 0.87 | TDP1 (0.38) | TDP1KDM4ELMNAALDH1A1GAA | |
| SCHEMBL13487522 | 0.87 | TDP1 (0.38) | TDP1KDM4ELMNAALDH1A1GAA | |
| SCHEMBL13487295 | 0.86 | KDM4E (0.35) | TDP1KDM4ELMNAALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100045170-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-25 | — | — | US | disclosed |
| US-20100045170-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100045170-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | OCIAD1, OCIAD2, ORMDL3 | TDP1 1904/4885KDM4E 3671/4885LMNA 3760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.